- Home
- AVTX vs SKYE Comparison
AVTX vs SKYE Comparison
Compare AVTX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- SKYE
- Stock Information
- Founded
- AVTX 2011
- SKYE 2012
- Country
- AVTX United States
- SKYE United States
- Employees
- AVTX N/A
- SKYE 16
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- SKYE Health Care
- Exchange
- AVTX Nasdaq
- SKYE Nasdaq
- Market Cap
- AVTX 57.4M
- SKYE 115.9M
- IPO Year
- AVTX 2015
- SKYE N/A
- Fundamental
- Price
- AVTX $4.86
- SKYE $4.30
- Analyst Decision
- AVTX Strong Buy
- SKYE Buy
- Analyst Count
- AVTX 7
- SKYE 6
- Target Price
- AVTX $31.00
- SKYE $16.60
- AVG Volume (30 Days)
- AVTX 99.0K
- SKYE 2.1M
- Earning Date
- AVTX 08-11-2025
- SKYE 08-08-2025
- Dividend Yield
- AVTX N/A
- SKYE N/A
- EPS Growth
- AVTX N/A
- SKYE N/A
- EPS
- AVTX N/A
- SKYE N/A
- Revenue
- AVTX $441,000.00
- SKYE N/A
- Revenue This Year
- AVTX N/A
- SKYE N/A
- Revenue Next Year
- AVTX N/A
- SKYE N/A
- P/E Ratio
- AVTX N/A
- SKYE N/A
- Revenue Growth
- AVTX N/A
- SKYE N/A
- 52 Week Low
- AVTX $3.39
- SKYE $1.14
- 52 Week High
- AVTX $16.00
- SKYE $7.47
- Technical
- Relative Strength Index (RSI)
- AVTX 56.99
- SKYE 67.91
- Support Level
- AVTX $4.63
- SKYE $3.92
- Resistance Level
- AVTX $4.99
- SKYE $4.75
- Average True Range (ATR)
- AVTX 0.28
- SKYE 0.66
- MACD
- AVTX 0.01
- SKYE 0.09
- Stochastic Oscillator
- AVTX 87.64
- SKYE 60.70
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.